Recombinant Human GLP2 Protein，His

Glucagon-like peptide-2 (GLP-2) is an intestinal incretin hormone predominantly secreted by L-cells in the gut in response to nutrient intake. It plays a significant role in promoting intestinal growth, enhancing mucosal integrity, and regulating food intake, making it a focus of research for gastrointestinal health and metabolic disorders. Recombinant GLP-2 protein has garnered attention for its potential therapeutic applications in conditions such as short bowel syndrome, inflammatory bowel disease, and other gastrointestinal diseases characterized by mucosal damage and malabsorption. Studies have shown that GLP-2 can stimulate intestinal epithelial cell proliferation, increase intestinal blood flow, and reduce gastric emptying, contributing to improved nutrient absorption and overall gut function. The development of recombinant GLP-2 has enabled detailed investigations into its pharmacological effects and mechanisms of action, paving the way for innovative treatments aimed at enhancing intestinal health and managing metabolic syndromes. Given the growing prevalence of gastrointestinal disorders and the demand for effective therapies, the exploration of GLP-2 as a recombinant protein underscores its potential to revolutionize the management of these conditions, offering new avenues for improving patient outcomes and quality of life. The ongoing research surrounding GLP-2 continues to elucidate its complex roles in the gastrointestinal system and to justify the development of synthetic analogs for clinical use.